Constructive Bio, Xeltis, Mi Healthcare
Patchwork Health Raises £20M in Series B Funding
Patchwork Health, a London, UK-based healthcare workforce platform, raised £20m in Series B funding.
The round was led by Perwyn and backed by Praetura Ventures and KHP Ventures. They were joined by a range of prominent angel investors, including Monzo founder Tom Blomfield and Social Chain Co-founder Dominic McGregor.
The company intends to use the funds to continue to:
- further strengthen their customer-facing teams,
- accelerate the development of new products and features for their healthcare clients,
- expand into international markets, and
- bring their services to new areas of health and a wider range of sectors.
Founded in 2016 by NHS medics Dr Anas Nader and Dr Jing Ouyang, Patchwork Health offers a range of additional solutions, including:
- ‘collaborative staff banks’, which help healthcare organisations team up with others in the same region to widen their temporary staffing pool;
- an innovative new rostering solution which enables more flexible, sustainable staffing for permanent healthcare staff; and
- an Agency Manager which makes it easier for managers to select appropriate temporary staff from external agencies when necessary.
Patchwork Insights also provides managers with comprehensive data oversight, to monitor staffing trends, shift fill rates and pay rate escalations, and reliably plan ahead to prevent staffing gaps.
Patchwork Health Raises £20M in Series B Funding
Patchwork Health, a London, UK-based healthcare workforce platform, raised £20m in Series B funding
Dutch medtech startup Xeltis secures €15 million to develop pioneering medical treatments
Xeltis, a Dutch medtech startup, has secured €15 million of fresh investment from Chinese firm, Grand Pharma. The startup is developing medical devices to treat cardiovascular disease and as a result, aims to lessen the incidence of CKD.
Chronic Kidney Disease (CKD) is reported to affect 9% of the population – and its prevalence is growing due to a simultaneous increase in cardiovascular diseases around the world (including diabetes, hypertension and diabetes). CKD is now accounting for more deaths than breast and prostate cancers combined. Traditional hemodialysis is overwhelmed with demand, and patients are now experiencing long waiting times to get access to the treatment they need.
Xeltis is developing polymer-based restorative devices for cardiovascular treatment. The restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for which clinical trials are ongoing. The aim is that these devices can provide more durable, transformative treatment options for patients worldwide.
To develop the product, the Dutch startup has just picked up €15 million in new investment.
Dutch medtech startup Xeltis secures €15 million to develop pioneering medical treatments | EU-Startups
Xeltis, a Dutch medtech startup, has secured €15 million of fresh investment from Chinese firm, Grand Pharma. The startup is developing medical devices to
Re-engineering biology, Constructive Bio scores $15 million to make new class of enzymes
Cambridge-based biotech startup Constructive Bio has raised $15 million in funding to create technology for producing synthetic genomes and reprogramming the genetic code of living organisms. This, in turn, will allow scientists to write entire genomes from scratch.
The new funding will drive the company’s commercial development and make its technology accessible to labs working on therapeutics and antibiotics, enhanced agriculture, manufacturing and materials and more. The seed round was led by Ahren alongside Amadeus Capital Partners, General Inception and OMX Ventures.
The startup aims to develop methods for reprogramming the genetic code of living organisms, rewriting the near-universal genetic code of natural life to create organisms that use new genetic codes. According to the company, the new organisms deliver remarkable properties. They are resistant to a wide variety of viruses, they can be programmed to make new unnatural, or synthetic, polymers, and even perform entirely new functions.
The company also holds an exclusive licence from the Medical Research Council to IP developed by the Chin Lab at the Medical Research Council Laboratory of Molecular Biology based in Cambridge, UK.
Re-engineering biology, Constructive Bio scores $15 million to make new class of enzymes - Tech.eu
The startup aims to develop methods for reprogramming the genetic code of living organisms, rewriting the near-universal genetic code of natural life to create organisms that use new genetic codes
Probo Medical Acquires Mi Healthcare
Probo Medical, a Tampa, Fla.-based global provider of medical imaging equipment, parts, repair, and service, acquired Mi Healthcare, a Liverpool, England, UK-based provider of medical imaging equipment and services to public and private healthcare facilities.
The terms of the transaction were not disclosed.
With the acquisition of Mi Healthcare, Probo will extend the reach of its diagnostic imaging equipment sales, rentals and service capabilities throughout the UK.
Established in 1995 and led by Tim Dickinson and Mark Edwards, Mi Healthcare provides medical imaging equipment and services to public and private healthcare facilities across the UK. Its team provides ultrasound and x-ray sales, rental and service solutions across the UK with offices in both England and Scotland.
Led by Michael Asmer, CEO, Probo Medical is a diversified supplier of refurbished diagnostic imaging equipment sales, service, rental, repair and installation of a vast array of imaging equipment, including ultrasound, c-arm, x-ray, mammography, fluoroscopy, MRI and CT. The company is backed by Avista Capital Partners, a New York-based private equity firm with more than 40 growth-oriented healthcare businesses globally.
Probo Medical Acquires Mi Healthcare
Probo Medical, a Tampa, Fla.-based global provider of medical imaging equipment, parts, repair, and service, acquired Mi Healthcare, a Liverpool, England, UK-based provider of medical imaging equipment and services to public and private healthcare facilities
Arsenal Capital Partners Closes Two New Funds Totaling $5.4 Billion
Arsenal Capital Partners, a NYC-based private equity firm that specializes in investments in industrial growth and healthcare companies, completed fundraising for two new funds, totaling $5.4 billion in capital commitments.
In details:
- Arsenal Capital Partners VI LP (together with its parallel funds, “Fund VI”) closed with $4.3 billion in capital commitments,
- Arsenal Capital Partners Growth LP (together with its parallel funds, the “Growth Fund”) closed with $1.1 billion in capital commitments.
Fund VI and the Growth Fund’s investor base is comprised of leading public and corporate pension plans, family offices, endowments and foundations, and financial institutions, including The University of California’s Office of the Chief Investment Officer (UC Investments), California State Teachers’ Retirement System, California Public Employees’ Retirement Systems, affiliates of APG Asset Management, The Oregon Public Employees Retirement Fund, affiliates of IIP A/S, and Minnesota State Investment Board.
Fund VI will focus on investments in industrials and healthcare businesses with proven technologies and solutions positioned to deliver high performance and value-add to their customers.
The Growth Fund will execute a similar strategy in the same markets but pursue investments in next generation, emerging technology businesses poised to apply innovation to generate very high growth.
In both of these funds, Arsenal will apply its company building capabilities to help businesses achieve significant organic growth and facilitate strategic acquisitions to extend their offerings and to solidify leadership positions in their respective markets.
Since its inception in 2000, Arsenal has raised institutional equity investment funds totaling over $10 billion, completed more than 250 platform and add-on acquisitions, and achieved more than 30 realizations.
